Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01839916 · OUTCOME

Progression Free Survival (PFS)

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
2 years

What was measured

Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.

Analysis population: Patients received at least one DLI Treatment.

Groups in this outcome

Treatment (DLI)

Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (DLI)36

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (DLI)43Not reported2963.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        29
        upper Limit
        63.9
        value
        43
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (DLI)
param Type
NUMBER
population Description
Patients received at least one DLI Treatment.
reporting Status
POSTED
time Frame
2 years
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice